Emmanuel Sevin

2.1k citations

39 papers · 1.3k indexed · h-index 13

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 2%
- Renal cell carcinoma treatment
- Cancer-related cognitive impairment studies

Papers in

Geriatrics and Gerontology 3
Cancer Research 11
- Cancer Genomics and Diagnostics 9

Co-authors: Bernard Escudier Christine Chevreau Alain Ravaud Sylvie Négrier David Pérol R. Delva Gwénaëlle Gravis Omi Parikh
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (6 papers)Gynecologic Oncology (2 papers)Clinical Genitourinary Cancer (2 papers)Cancer (1 paper)
Partner nations: France Luxembourg United Kingdom

In The Last Decade

Emmanuel Sevin

37 papers receiving 1.3k citations

Peers

Countries citing papers authored by Emmanuel Sevin

Since Specialization

Citations

This map shows the geographic impact of Emmanuel Sevin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Sevin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Sevin more than expected).

Fields of papers citing papers by Emmanuel Sevin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Sevin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Sevin. The network helps show where Emmanuel Sevin may publish in the future.

Co-authors

The 25 scholars most cited alongside Emmanuel Sevin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emmanuel Sevin Line = papers co-authored together Emmanuel Sevin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Utilizing CT and MRI in Assessing Peritumoral Neovascularization in Renal Cell Carcinoma: A Comprehensive Analysis of Histological Subtypes and Tumor Characteristics by Imaging Current Medical Imaging Formerly Current Medical Imaging Reviews ·Van Thinh Phung, Emmanuel Sevin, İbrahim İnan, A. Özdemir Aktan, G. Tandon, Salwa Asaad Dagher, T. Terranova	2024	1
2	Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies Clinical Genitourinary Cancer ·Angéline Denouel, Natacha Heutte, Bernard Escudier, Jean‐Emmanuel Kurtz, Mélanie Dos Santos, Nadine Longato, Laurence Desrues, Sarah Dauchy, Marie Lange, Emmanuel Sevin, Chantal Rieux, Bénédicte Clarisse, Hélène Castel, S. I. Umidowa, Florence Joly	2018	4
3	Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial Annals of Oncology ·Stéphane Oudard, I. Latorzeff, Armelle Caty, Laurent Miglianico, Emmanuel Sevin, B.P Krustalev, R. Delva, Frédéric Rolland, Christine Chevreau, Frank Priou, Philippe Beuzeboc, Gwénaëlle Gravis, Claude Linassier, Tokudome Yuko, Éric Voog, Nelson JR, Xavier Muracciole, O Mhhhhh, Sarka Vavreckova, Stéphane Culine	2017	3
4	Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort Clinical Genitourinary Cancer ·Damien Pouessel, Sylvie Bastuji‐Garin, Nadine Houédé, Dimitri Vordos, Yohann Loriot, Christine Chevreau, Emmanuel Sevin, Philippe Beuzeboc, Alexandre de la Taille, Aurélie Le Thuaut, Yves Allory, Stéphane Culine	2016	11
5	First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG) Annals of Oncology ·Alain Ravaud, Stéphane Oudard, Marc de Fromont, Christine Chevreau, Gwénaëlle Gravis, Sylvie Zanetta, Christine Théodore, Marta Jimenez, Emmanuel Sevin, Brigitte Laguerre, Frédéric Rolland, M. Ouali, Stéphane Culine, Bernard Escudier	2015	121
6	Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy Nuclear Medicine Communications ·Dubey Amol, Audrey Emmanuelle Dugué, Emmanuel Sevin, 誓子村井, F. Lesaunier, Florence Joly, Nicolas Aide	2015	7
7	VOTRAGE study pazopanib in vulnerable elderly patients after geriatric assessment—A phase I study with geriatric criteria. Journal of Clinical Oncology ·Loı̈c Mourey, Alain Ravaud, Laurence Digue, C. Terret, Emmanuel Sevin, Thomas Filleron, Laurent Balardy	2015	1
8	A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma Annals of Oncology ·Frédèric Selle, Emmanuel Sevin, Isabelle Ray‐Coquard, Véronique Mari, Dominique Berton-Rigaud, Laure Favier, Michel Fabbro, Anne Lesoin, Alain Lortholary, Éric Pujade-Lauraine	2014	8
9	Cognitive dysfunctions in elderly cancer patients: A new challenge for oncologists Cancer Treatment Reviews ·Marie Lange, Olivier Rigal, Bénédicte Clarisse, Bénédicte Giffard, Emmanuel Sevin, Jacob Eyferth, Francis Eustache, Florence Joly	2014	89
10	Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial Annals of Oncology ·Claire Falandry, B. Weber, Aude-Marie Savoye, Fabien Tinquaut, Olivier Trédan, Emmanuel Sevin, Laëtitia Stefani, Francesco Savinelli, Antje Rinne, J Salvat, Éric Pujade-Lauraine, Gilles Freyer	2013	86
11	Is docetaxel-prednisone (DP) feasible in frail elderly (75+) patient with castration-resistant metastatic prostate cancer (CRMPC)? A prospective randomized study after geriatric assessment from gerico and getug unicancer groups Journal of Geriatric Oncology ·Loı̈c Mourey, Gwénaëlle Gravis, Emmanuel Sevin, Frank Priou, Emmanuelle Bompas, Kaius Munhoz de Paula, Nadine Houédé, Élisabeth Carola, R. Moeseler, I. Latorzeff, V.S. Kharchyk, Thomas Filleron	2013	1
12	Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer EJNMMI Research ·Renaud Ciappuccini, Martín Cuesta Vivar, Natacha Heutte, Emmanuel Sevin, 三代子桑原, Stéphane Bardet	2012	4
13	Cancer du rein métastatique : évolution à l’arrêt du traitement antiangiogénique chez des patients en réponse complète, à propos de cinq cas Bulletin du Cancer ·Julien Demiselle, Stéphanie Lheureux, Bénédicte Clarisse, Emmanuel Sevin, Florence Joly	2011	2
14	Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial The Lancet Oncology ·Sylvie Négrier, Gwénaëlle Gravis, David Pérol, Christine Chevreau, R. Delva, Jacques‐Olivier Bay, Ellen Blanc, Céline Ferlay, Lionnel Geoffrois, Frédéric Rolland, Éric Legouffe, Emmanuel Sevin, Brigitte Laguerre, Bernard Escudier	2011	172
15	Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial Gynecologic Oncology ·Florence Joly, Emmanuel Sevin, Alain Lortholary, Frank Priou, J.F. Paitel, Michel Fabbro, M. Henry‐Amar, دريدش حلمي, Hugues Bourgeois	2009	6
16	Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study Gynecologic Oncology ·Florence Joly, Thierry Petit, Patricia Pautier, Emmanuel Guardiola, F. Mayer, Annick Chevalier-Place, R. Delva, Emmanuel Sevin, M. Henry‐Amar, Hugues Bourgeois	2009	5
17	First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) Journal of Clinical Oncology ·Alain Ravaud, Stéphane Oudard, Gwénaëlle Gravis, Emmanuel Sevin, Sylvie Zanetta, C Théodore, Marc de Fromont, BERENIKA BYSZEWSKI, Geneviève Chêne, Bernard Escudier	2009	27
18	First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma Annals of Oncology ·Bohuslav Melichar, P. Koralewski, Alain Ravaud, A Płużańska, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, R. Delva, Emmanuel Sevin, Sylvie Négrier, J McKendrick, Armando Santoro, Pavel Pisa, Bernard Escudier	2008	71
19	Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis Cancer ·Sylvie Négrier, David Pérol, Alain Ravaud, Christine Chevreau, Jacques‐Olivier Bay, R. Delva, Emmanuel Sevin, Armelle Caty, Bernard Escudier	2007	135
20	Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial Journal of Clinical Oncology ·P. Chinet-Charrot, 義仁筑紫, Hugues Bourgeois, Alain Lortholary, Bernard Leduc, Frank Priou, Denise Mourad, Emmanuel Sevin, دريدش حلمي, M. Henry‐Amar	2005	0

About Emmanuel Sevin

Emmanuel Sevin is a scholar working on Geriatrics and Gerontology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine, having authored 39 papers that have together received 1.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (13 papers), Cancer Genomics and Diagnostics (9 papers), Renal and related cancers (7 papers), Cancer Treatment and Pharmacology (7 papers), Prostate Cancer Treatment and Research (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Ovarian cancer diagnosis and treatment (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). The work is most often cited by research in Cancer Research (538 citations), Pulmonary and Respiratory Medicine (1.0k citations), Geriatrics and Gerontology (59 citations), Oncology (350 citations) and Molecular Biology (712 citations). Emmanuel Sevin has collaborated with scholars based in France, Luxembourg and United Kingdom. Frequent co-authors include Bernard Escudier, Christine Chevreau, Alain Ravaud, Sylvie Négrier, David Pérol, R. Delva, Gwénaëlle Gravis, Sylvie Négrier, Omi Parikh and Ugo De Giorgi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Gynecologic Oncology, Clinical Genitourinary Cancer and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact